A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of JKN2403 Tablets in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 29 Jan 2026
At a glance
- Drugs JKN 2403 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Joincare Pharmaceutical
Most Recent Events
- 29 Jan 2026 New trial record